HMN 2025: How New blood biomarker predicts development of Alzheimer’s illness even in its earliest phases

A group of researchers on the Sant Pau Research Institute (IR Sant Pau) has demonstrated that the plasma biomarker p-tau217, obtained via a easy blood check, can predict the medical development of Alzheimer’s illness even in its earliest phases, when signs usually are not but evident. The study, published within the journal Neurology, reinforces the position of blood checks in the way forward for diagnosing and monitoring dementias.

The study, performed throughout the framework of the SPIN cohort (Sant Pau Initiative on Neurodegeneration), included 731 people with and with out cognitive impairment who had been adopted for a mean of as much as 10 years.

The researchers analyzed ranges of p-tau217—a selected type of the tau protein related to neurodegeneration—and noticed that this marker not solely correlates with the presence of Alzheimer’s illness but in addition allows prediction of the speed of cognitive decline and development to extra superior phases of the illness, together with dementia.

“This marker has monumental potential as a medical software. It not solely precisely identifies Alzheimer’s illness, but in addition permits us to estimate how briskly it can progress—a necessary think about making therapeutic choices,” says Dr. Ignacio Illán, researcher within the Neurobiology of Dementia group and neurologist at Sant Pau Hospital, who led the research.

For her half, Judit Selma-González, first writer and analysis neuropsychologist, additionally from the Neurobiology of Dementia group, highlights that “one of the vital related findings is that p-tau217 permits us to determine individuals who don’t but have cognitive signs however are at greater danger of growing the illness within the quick or medium time period. This may also help us higher choose sufferers eligible to take part in medical trials of disease-modifying remedies.”

An accessible various

Until now, probably the most dependable biomarkers for detecting and monitoring Alzheimer’s illness have required invasive methods corresponding to lumbar puncture (to investigate cerebrospinal fluid) or expensive procedures corresponding to positron emission tomography (PET). The use of plasma p-tau217 affords a noninvasive, extra accessible, and inexpensive various with each medical and analysis functions.

The study confirmed that p-tau217 ranges elevated progressively from the preclinical phases to the superior phases of dementia, and had been independently related to the next danger of cognitive decline (measured, amongst different instruments, with the Mini-Mental State Examination) and conversion to dementia. In truth, the marker confirmed higher prognostic capacity than its cerebrospinal fluid equal, p-tau181, which is broadly used immediately.

Clinical functions and a promising future

This advance is especially related within the present context, where disease-modifying remedies—corresponding to anti-amyloid antibodies—are already being authorised, and their use is determined by the stage of Alzheimer’s illness development. The risk of utilizing a blood check to find out this medical stage and monitor its development represents a serious step towards extra personalised and exact drugs.

“In a reminiscence clinic, gaining access to this data via a blood check opens up prospects that had been beforehand restricted to extremely specialised facilities,” notes Dr. Illán.